EBM簡介及臨床應用

講師:高雄長庚藥劑部康玉嬋藥師

日期:2012年9月4日

什麼是實證醫學

*實證醫學 (EBM, Evidence-Based Medicine) 以流行病學和統計學的方法,從龐大的醫學資料庫中嚴格評讀、綜合分析找出值得信賴的部分,並將所能獲得的最佳文獻證據,應用於臨床工作中,使病人獲得最佳的照顧。

實證醫學的三大要素


* "Evidence-based medicine is the integration of

best research evidence with

clinical expertise and

patient values"

- David L. Sackett



實證醫學的緣起

* 西元1992年Evidence-based Medicine一詞由加拿大McMaster大學Gordon Guyatt所領導的學術組織正式命名,引起世界對「實證醫學」的關

注。

The Rational Clinical Examination

Evidence-Based Medicine

A New Approach to Teaching the Practice of Medicine

Evidence-Based Medicine Working Group

A NEW paradigm for medical practice is emerging. Evidence-based medicine de-emphasizes intuition, unsystematic clinical experience, and pathophysiologic rationale as sufficient grounds for clinical decision making and stresses the examination of evidence from clinical research. Evidence-based medicine requires new skills of the physician, including efficient literature searching and the application of formal rules of evidence evaluating the clinical literature. An important goal of our medical residency program is to educate physicians

dose of phenytoin intravenously and the drug is continued orally. A computed tomographic head scan is completely normal, and an electroencephalogram shows only nonspecific findings. The patient is very concerned about his risk of seizure recurrence. How might the resident proceed?

The Way of the Past

Faced with this situation as a clinical clerk, the resident was told by her senior resident (who was supported in his view by the attending physician) that year is between 43% and 51%, and at 3 years the risk is between 51% and 60%. After a seizure-free period of 18 months his risk of recurrence would likely be less than 20%. She conveys this information to the patient, along with a recommendation that he take his medication, see his family doctor regularly, and have a review of his need for medication if he remains seizure-free for 18 months. The patient leaves with a clear idea of his likely prognosis.

A PARADIGM SHIFT

為何需要實證醫學

- ★ 臨床工作者在處置病人所面臨的問題時有許多不確定性,此時可以借助客觀可信的臨床研究結果,作為照顧病人的主要依據。
- *實證醫學是具有科學方法,以及人文特質的診療模式,並且以病人為中心,以問題為導向的臨床行動,正確的應用可以提昇整體的醫療品質,減少不必要的醫療浪費。

為何需要實證醫學

- * 電腦網路在實證醫學的應用扮演重要的角色, 文獻資料及最新的醫學進展可經由網路快速 的查詢,比傳統幾年才出版一次的教科書更 update。
- *集合學者回顧所有嚴謹發表或未發表的醫學文獻,做成**最接近正確的結論**,不須花很多時間 便能了解其要旨,利用這些資源可以節省閱讀 大量文獻的時間。

高雄長庚推廣實證醫學的情形

- * 醫學教育委員會下設實證醫學訓練小組。
- * 設置一名組長及十二位委員。
- ★ 成員包括:醫師、藥師、護理師、醫檢師、圖書館員..等。
- * 小組定期開會討論及規劃實證醫學相關課程。
- * 定期公告實證醫學相關課程、活動訊息。
- * 院內行政部門設置專責人員。



高雄長庚推廣實證醫學的情形

- * 針對新進實習、住院醫師安排實證醫學核心課程。
- ★ 每月辦理「EBM journal club」 由院內及院外專家參與指導。
- ★ 每年辦理院內實證醫學種子教師研習營教學,EBM 核心課程workshop,全院性EBM比賽。
- * 鼓勵人員公假公費參加參加院外實證醫學相關課程。



施行實證醫學的五大步驟 (5A)

- ≈1 Ask:將臨床情境形成一個可回答的臨床問題
- ≈2 Acquire: 尋找最佳的文獻證據
- ×3 Appraise: 嚴格評讀文獻
- ×4 Apply: 應用於病人身上
- ×5 Audit: 對過程進行稽核

施行實證醫學的五大步驟

* Ask:將臨床情境形成一個可回答的臨床問題



- * Acquire: 尋找最佳的文獻證據
- * Appraise: 嚴格評讀文獻
- × Apply: 應用於病人身上
- * Audit 對過程進行稽核

設PICO

- * P: Patient / Problem 病人或問題
- * I: Intervention 介入或指標
 - 某種治療、檢查、危險因子
- * C: Comparison 比較
 - 該治療和甚麼相比?
- × O: Outcome 結果
 - 您想要達成或避免甚麼?
- » Question

臨床問題分類

前景問題: 處理病人所需之特別知識的問題 Foreground Questions Background questions 背景問題:疾病一般知識性的問題 Novice Expert

前景問題 (Foreground Questions)

- * 實證醫學主要處理的是**前景問題**。
- * 養成提問的習慣,是改善醫療品質的第一步。
- ★問題的提出,決定後續該問題相關實證醫學的 實際操作步驟。

實證醫學的四大問題

- ×治療 (Therapy)
- ×診斷 (Diagnosis)
- × 預後 (Prognosis)
- × 病因/傷害 (Etiology/Harm)



施行實證醫學的五大步驟

- × Ask:將臨床情境形成一個可回答的臨床問題
- * Acquire: 尋找最佳的文獻證據

6S

- * Appraise: 嚴格評讀文獻
- * Apply: 應用於病人身上
- × Audit: 對過程進行稽核


證據金字塔




libraryguides.unh.edu

個案報告及個案係列報告


(Case Reports and Case-Series)




横切研究 (Cross-Sectional Survey)



個案對照研究 (Case-Control Studies)



世代研究 (Cohort Studies)




隨機對照試驗

(Ramdomized Controlled Studies)

- *研究方法:
 - 1. 屬於實驗性(experimental)研究。
 - 2. 以隨機方式將受試者分為治療組及控制組
 - ,比較兩組的狀況以了解試驗藥物的療效 及安全性,或某種處置之效益。
 - 3. 為目前臨床流行病學中公認證據力最強之 原始介入性研究設計 (primary interventional study)。

隨機對照試驗

(Ramdomized Controlled Studies)




Modified from library.downstate.edu

隨機對照試驗

(Ramdomized Controlled Studies)


* 雙盲(The double blind method):



系統性回顧 (Systematic Reviews)

- *研究方法:
 - 1. 集合多個**目的和方法相近**的研究整合在一 起進行分析。
 - 2. 若有將各研究的結果**合併進行統計**則稱為 統合分析 (meta-analysis)。

系統性回顧 (Systematic Reviews)



Modified from library.downstate.edu

系統性回顧 (Systematic reviews)

★ Traditional review 與 systematic review不同 之處:

Systematic	Traditional
全文只探討一個明確的問題	文章探討不只一個問題
詳細列出文獻搜尋方法	沒有列出文獻搜尋方法
詳細列出納入文獻的條件	沒有列出納入文獻的條件
將納入文獻整合起來,若將 其結果以統計之方法分析稱 統合分析(meta-analysis)	沒有將納入文獻整合起來

依據臨床問題尋找最佳文獻證據







Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence

Question	Step 1 (Level 1*)	Step 2 (Level 2*)	Step 3 (Level 3*)	Step 4 (Level 4*)	Step 5 (Level 5)	
How common is the problem?	surveys (or censuses)	Systematic review of surveys that allow matching to local circumstances**	Local non-random sample**	Case-series**	n/a	
, ,	of cross sectional studies with consistently applied reference standard and blinding	applied reference standard and blinding	Non-consecutive studies, or studies without consistently applied reference standards**	Case-control studies, or "poor or non-independent reference standard**	J	
	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial*	Case-series or case- control studies, or poor quality prognostic cohort study**	n/a	
intervention help? (Treatment Benefits)			Non-randomized controlled cohort/follow-up study**	Case-series, case-control studies, or historically controlled studies**	Mechanism-based reasoning	
COMMON harms?	trials, systematic review	or (exceptionally) observational	Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning	
	trials or <mark>n-of-1 trial</mark>	Randomized trial or (exceptionally) observational study with dramatic effect				
	Systematic review of randomized trials	Kandomized trial	Non -randomized controlled conort/follow-up study**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning	

實證資源:6\$



實證資源:6\$



Modified from Ann Intern Med. 2009 Sep 15;151(6):JC3-2, JC3-3.

同義字的設定


* 增加搜尋的敏感度:

原始單字	同義字1	同義	同義字2	
P (OR	OR) AND	
I (OR	OR) AND	
C (OR	OR) AND	
O (OR	OR) AND	

PubMed檢索







PubMed檢索

- * 檢索技巧:
 - ◆布林邏輯(Boolean):

AND、OR、NOT需大寫,二個以上加「()」由左算到右、加括弧的先運算。

如: antiplatelet AND (aspirin OR clopidogrel)


◆ **切截(Truncate)**:將 * 放在字尾進行模糊查詢。 例:obes*:obese, obesity…

如結果超過六百個變化字,系統將出現警示語。

◆單字與片語:

用雙引號" 讓系統將多個關鍵字視為片語 lung cancer與" lung cancer"


PubMed - Mesh Database檢索




Medical Subject Headings :


- ◆醫學標題表之簡稱。是美國國家醫學圖書館(NLM) 針對生物醫學資料所整理出的主題詞彙。
- ◆ 對同一概念採用固定的詞彙表達方式,以達到控制 詞彙目的,方便生物醫學領域的學者或從業人員彼 此間的溝通。

PubMed - Mesh Database檢索




使用MeSH連接PubMed搜尋之文獻篇數





直接使用PubMed搜尋之文獻篇數



直接使用PubMed搜尋之文獻篇數

★ 若不需要搜尋MeSH term,用"" 雙引號括號起來即可:




1. Vogel CW, Hernandez BY, Morita SY, Wilkens LR.

6. Harbouring HCV Replicon and in Replicon-Cured Cells.
Okoli AS, Raftery MJ, Mendz GL.
Int J Hepatol. 2012;2012:501671. Epub 2012 Jul 30.
PMID: 22900193 [PubMed - as supplied by publisher] Free Article


Emerging Putative Biomarkers: The Role of Alpha 2 and 6 Integrins in Susceptibility,
Treatment, and Prognosis.
Marthick JR, Dickinson JL.
Prostate Cancer. 2012;2012:298732. Epub 2012 Jul 31.
PMID: 22900191 [PubMed - as supplied by publisher] Free Article

PubMed檢索



PubMed - Clinical Queries檢索





The Cochrane Library檢索



from The Cochrane Collaboration

SEARCH

Title, Abstract or Keywords

Advanced Search > MeSH Search >

Search History > Saved Searches >

COCHRANE REVIEWS

By Topic New Reviews Updated Reviews A-Z By Review Group

OTHER RESOURCES

Other Reviews Trials Methods Studies Technology Assessments Economic Evaluations

Advanced Search

MeSH Search | Search History | Saved Searches

Enter a term below and click Search to continue.

Search For:

ln:

To search using field labels (e.g. heart:ti) use the Search History page.

	Enter search term 1	Search All Text	•
AND 🔻	Enter search term 2	Record Title	V
AND 🔻	Enter search term 3	Author	V
AND 🔻	Enter search term 4	Abstract	•
AND 🔻	Enter search term 5	Keywords	•
	Search Go directly to Search History		

檢索技巧與 Pubmed相同

ADOUTING

Tip No. 1:

Boolean operators AND, OR, and NOT can be selected from the pulldown selection boxes or entered directly within the search text boxes. Use parentheses to separate components when entering complex search directly in text box with mixed Boolean operators.

Example: (colchicine AND liver) AND (fibrosis OR cirrhosis)


Tip No. 2:

The AND operator is used by default between search terms. The string brain stem will match records where both words are included in any order or provingly.

Restrict Search by Product

- All of The Cochrane Library
- Cochrane Database of Systematic Reviews (Cochrane Reviews)

The Cochrane Library檢索



實證醫學資料庫

*考科藍實證醫學資料庫:

為推廣實證醫學於臨床上之應用,國衛院在全國醫學中心與醫學會的支持下,正持續進行CDSR摘要中文翻譯,成果已同步公布於國衛院考科藍實證醫學資料庫網站

http://clc.nhri.org.tw/admin/clcmain1.aspx,也可由國衛院-實證臨床指引平台連結。

施行實證醫學的五大步驟

- *Ask:將臨床情境形成一個可回答的臨床問題
- * Acquire: 尋找最佳的文獻證據
- * Appraise: 嚴格評讀文獻



- × Apply: 應用於病人身上
- × Audit 對過程進行稽核

文獻評讀三部曲

- * V: Validity/Reliability 效度/信度 我們能相信這篇文獻嗎?
- * I: Importance/Impact 重要性 我們相信了,但文獻的結論重要嗎?
- * P: Practice/Applicability 臨床適用性 這個結論可以應用在我們所有的病患嗎?

評讀工具

Publications Training & Education Home About the CEBM EBM Tools **Resource Centre** Bloa Contact Search EVIDENCE BASED MEDICINE Quickfinder

CEBM > EBM Tools > Critical Appraisal > Overview

Asking Focused Questions

Finding the Evidence

Study Designs

Explanations and Examples

Critical Appraisal Sheets

EBM Calculators

CATmaker

Making a Decision

Evaluating Performance

Designing Research

Critical Appraisal

This section contains useful tools and downloads for the critical appraisal of medical evidence. Example appraisal sheets are provided together with several helpful examples. Below, you can download our calculators, as well as our PC-based software tool CATmaker.



Critical Appraisal Sheets

Systematic Review Critical Appraisal Shee

Diagnostic Critical Appraisal Sheet

Prognosis Critical Appraisal Sheet

RCT Critical Appraisal Sheet

PICO Critical Appraisal Sheet (PDF) PICO Critical Appraisal Sheet (MS-Word)

Educational Prescription Critical Appraisa Sheet (PDF)

Calculators

All-purpose 2x2 Table

The "CATmakers Scratching Post" Download (Adobe Flash format)

Interactive Nomogram

Generates nost-test probabilities from

Explanations & Examples

Pre-test probability

SpPin and SnNout

Likelihood Ratios

NNTs

CATmaker

CATmaker is a computer-assisted critical appraisal tool, which helps you create Critically





from all over the world have trained at the CEBM in Oxford.

Latest courses and workshops

Teaching Evidence-based Practice (5 days) 3rd-7th September 2012 More Information

Workshop on Evidence-Based **Practice**

(1 day) 30th November 2012

評讀工具



Critical Appraisal Skills Programme Making sense of evidence

Search:

Go

Home

Find, Appraise, Act

Workshops

About CASP

Contact us

News

Welcome to the CASP UK Website

The Critical Appraisal Skills Programme helps people to find and interpret the best available evidence from health research.

It is part of an international network that shares a commitment to selfdirected learning and promoting better understanding of science.

On this website you can find out about the CASP approach, download the CASP checklists, and find out what sort of workshops we offer to help improve your appraisal skills.

You can even commission one that is custom designed for your needs.

Introduction by Amanda Burls:



Checklists

Download the CASP critical appraisa checklists for:

- Randomised Controlled Trials
- Systematic Reviews
- · Cohort Studies Case-Control Studies
- Qualitative Studies

Workshops

The 2012 CASP International Training Week was held at Kellogg College from 16th-20th April. We are in the process of arranging the next training week, which is to be held from 18th-22nd March 2013. If you would like to be notified when booking is open, please let us know via the 'contact us'



Network News

CASP example used in this training and support resource for INVOLVE. Click here for more details.

24th May 2012: Webinar - Critical Appraisal Skills Programme's (CASP) Suite of Critical Appraisal Tools with the National Collaborating Centre for

× P值:

- (1) p值是機率,以檢定統計量(test statistic)計算而得,用以衡量樣本資料支持(或不支持)虛無假設的程度。其值介於 0 與 1 之間。
- (2) 我們常應用的P值,是比較兩組是否有顯著的差異,但P值深受樣本數(sample size)影響,只要樣本數夠大,就算只有些微差異也變得顯著,統計學上的顯著不一定代表臨床上有重大顯著意義。

× 效果值 (effect size):

- (1) 是一種標準化的效果數據呈現,可讓論文讀者客觀 的評估治療效果。
- (2) 讓讀者用以評估RCT結果的臨床意義。
- (3) 可用於設計/執行RCT時power的計算。
- (4) 可用於meta-analysis of RCTs的結果呈現。

× 95%信賴區間 (95% Confidence interval (CI)):

指在某一信賴程度內,由樣本統計量所求出預期可以包括母群體的範圍,用以評估不確定性的指標。通常設為95%,代表我們有95%的信心確定母群體的真正數值會落在這個範圍內。



× Validity (信度/效度):

- 1. 這些病人的分組是隨機分派的嗎?(randomized?)
- 2. 分派的方法是否保密?(allocation concealment?)
- 3. 分派的兩組在治療開始時的baseline是否相似?若不相似,是否用統計的方法來修正,或增加被研究者的數目?
- 4. 除了研究治療項目以外,其他的治療在各組間是否相同?

× Validity (信度/效度):

5. 治療方法對病患、醫護人員、研究者是否保持盲性 (non-blinded, single blinded, double blinded, or

triple blinded)?

6. 追蹤是否完整? (follow-up duration) (失聯者少20%

為佳)

7. 分析時是否利用intention-to-treat analysis分析? (vs.

per protocol analysis)

治療意向分析法 (intention to treat analysis, ITT):

是指研究結果分析應包含原先列入研究之所有對象之結果,不論其最後是否背離原始之分組治療模式,雖然這些背離的個案可能會影響各組之結果,但**此種方**式保留了隨機取樣之精神,且其結果較可能代表在原始設計情況下海域病域養變基種治療必真正的發െ與講論文

* 依計畫書分析法 (per-protocol analysis, PP) : 排除未遵守試驗計劃書、中途退出之受試者,僅納入符合試驗計劃書執行方式的受試者進行資料分析。

	死亡人數	存活人數	總計
治療組	10	90	100
對照組	15	85	100
總計	25	175	200

- × 治療組死亡率(EER):10/100=0.1=10%
- * 對照組死亡率 (CER):15/100=0.15=15%
- * 相對風險比(RR): EER/CER=0.1/0.15=0.67
- 絶對風險下降率(ARR): |CER-EER|=|15%-10%|=5%
- * 相對風險下降率 (RRR): ARR/CER=5%/15%=0.33=33%
- ★ 益一治療數 (NNT):1/ARR=1/5%=20

★ NNT (number needed to treat) 益一治療
:=1/ARR

使一位病人達到實驗組治療之有益結果(或預防產生一個不良結果)所需治療的病人數目。

★ NNH (number needed to harm) 害一治療
:=1/ARI

對多少病人數目進行實驗組療法,與對照組做比較後,會有多一個病人產生不良副作用。

RRR v.s. ARR v.s. NNT


- × 相對風險下降率 (RRR)
- × 絕對風險下降率 (ARR)
- × 益一治療數 (NNT)

	CER EER	RRR	ARR	NNT
治療 1	50% 30%	40% = (50-30) / 50	20%	5人
治療 2	5.0% 3.0%	40%	2.0%	50 人
治療 3	0.5% 0.3%	40%	0.2%	500人

× Validity (信度/效度):

- 1. 這篇文獻探討的問題為何?
- 2. 沒有遺漏重要的文獻?
- 3. 選擇文獻的準則適當?
- 4. 選擇的文獻有足夠的效度而能回答所問的問題?
- 5. 各研究的結果相似?

× 數狀圖 (Forest plot)判讀:




1. Line of no effect

	No with recu headache/No i				
Study	Dexamethasone group	Placebo group	Relative risk (fixed) (95% CI)	Weight (%)	Relative risk (fixed) (95% CI)
Innes 1999	9/49	22/49		14.97	0.41 (0.21 to 0.80)
Jones 2003	8/34	10/36		6.61	0.85 (0.38 to 1.89)
Baden 2006	4/31	8/24		6.14	0.39 (0.13 to 1.13)
Donaldson 2006	21/57	18/42		14.10	0.86 (0.53 to 1.40)
Fiesseler 2006	19/44	20/41		14.09	0.89 (0.56 to 1.40)
Friedman 2007	39/106	43/99		30.26	0.85 (0.61 to 1.19)
Rowe 2007	14/64	20/62		13.83	0.68 (0.38 to 1.22)
Total (95% CI)	385	353	•	100.00	0.74 (0.60 to 0.90)
Test for heterogeneity:	: χ ² =6.21, df=6, P=0.4	$0, 1^2 = 3.4\%$		- 10	
Test for overall effect:	z=3.01, P=0.003		0.1 0.2 0.5 1 1 2	5 10	
			Favours dexamethasone	Favours placebo	

2. Point estimate and 95% CI

	No with recu headache/No i										
Study	Dexamethasone group	Placebo group				lative ris ed) (95%				Weight (%)	Relative risk (fixed) (95% CI)
Innes 1999	9/49	22/49		\in	-)				14.97	0.41 (0.21 to 0.80)
Jones 2003	8/34	10/36				-				6.61	0.85 (0.38 to 1.89)
Baden 2006	4/31	8/24			-	<u> </u>				6.14	0.39 (0.13 to 1.13)
Donaldson 2006	21/57	18/42				_				14.10	0.86 (0.53 to 1.40)
Fiesseler 2006	19/44	20/41			_					14.09	0.89 (0.56 to 1.40)
Friedman 2007	39/106	43/99								30.26	0.85 (0.61 to 1.19)
Rowe 2007	14/64	20/62			-	-				13.83	0.68 (0.38 to 1.22)
Total (95% CI)	385	353			•					100.00	0.74 (0.60 to 0.90)
Test for heterogeneity	/: χ ² =6.21, df=6, P=0.4	$0, 1^2 = 3.4\%$	0.1	0.7	0.5			-	10		
Test for overall effect:	z=3.01, P=0.003		0.1	0.2	0.5	T	2	5	10		
			Favoi dexa	ırs methasoı	ne				vours acebo		


3. Influence of studies on overall meta-analysis



Eyeball test

	No with recu headache/No i										
Study	Dexamethasone group	Placebo group				lative ri ed) (95%	57 T. Charles			Weight (%)	Relative risk (fixed) (95% CI)
Innes 1999	9/49	22/49		-		+				14.97	0.41 (0.21 to 0.80)
Jones 2003	8/34	10/36			·					6.61	0.85 (0.38 to 1.89)
Baden 2006	4/31	8/24			-	4				6.14	0.39 (0.13 to 1.13)
Donaldson 2006	21/57	18/42								14.10	0.86 (0.53 to 1.40)
Fiesseler 2006	19/44	20/41			_					14.09	0.89 (0.56 to 1.40)
Friedman 2007	39/106	43/99								30.26	0.85 (0.61 to 1.19)
Rowe 2007	14/64	20/62								13.83	0.68 (0.38 to 1.22)
Total (95% CI)	385	353			4					100.00	0.74 (0.60 to 0.90)
Test for heterogeneity	/: χ ² =6.21, df=6, P=0.4	$0, 1^2 = 3.4\%$									
Test for overall effect:	z=3.01, P=0.003		0.1	0.2	0.5	1	2	5	10		
			Favoi dexa	ırs methaso	ne	_		1717	ivours lacebo		

4. Heterogeneity (I²) = diversity between studies 25%: low; 25%-50%: medium; >50%: high



- ★ 0%~40%: might not be important
- * 30%~60%: may represent moderate heterogeneity
- ★ 50%~90%: may represent substantial heterogeneity
- x 75% ~ 100%: considerable heterogeneity

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

- Cochran chi-square (Cochran Q)
 - 確定有差異 (Definite heterogeneity) Cochran Q (P < 0.1)
 - 可能有差異 (Possible heterogeneity)
 Cochran Q is not statistically significant
 Cochran Q / degrees of freedom (Q/df) > 1
 - 有差異機會不大 (Heterogeneity unlikely)
 Cochran Q is not statistically significant
 Q/df < 1

5. Overall effect and the p value

	No with recu headache/No i										
Study	Dexamethasone group	Placebo group				lative ri ed) (95%				Weight (%)	Relative risk (fixed) (95% CI)
Innes 1999	9/49	22/49		· ·		- 1				14.97	0.41 (0.21 to 0.80)
Jones 2003	8/34	10/36			-		_			6.61	0.85 (0.38 to 1.89)
Baden 2006	4/31	8/24			-	<u>-</u> -				6.14	0.39 (0.13 to 1.13)
Donaldson 2006	21/57	18/42			_					14.10	0.86 (0.53 to 1.40)
Fiesseler 2006	19/44	20/41			-	-				14.09	0.89 (0.56 to 1.40)
Friedman 2007	39/106	43/99			_	-				30.26	0.85 (0.61 to 1.19)
Rowe 2007	14/64	20/62			-	+				13.83	0.68 (0.38 to 1.22)
Total (95% CI)	385	353					5			100.00	0.74 (0.60 to 0.90
Test for heterogeneity	/: χ ² =6.21, df=6, P=0.4	$0, 1^2 = 3.4\%$			0.5	4	_				
Test for overall effect:	z=3.0., P=0.003		0.1	0.2	0.5	1	2	5	10		5
			Favoi dexa	urs methaso	ne			5.733	vours acebo		_

- 6. Fix-effects model v.s. random-effects model
 - * 文獻間的異質性低,使用fix-effects model。
 - * 文獻間的異質性高·使用random-effects model。

	No with recurrent headache/No in group										6
Study	Dexamethasone group	Relative risk (fixed) (95% CI)							Weight (%)	Relative risk (fixed) (95% CI)	
Innes 1999	9/49	22/49		_	-	- [14.97	0.41 (0.21 to 0.80
Jones 2003	8/34	10/36					_			6.61	0.85 (0.38 to 1.89
Baden 2006	4/31	8/24			-					6.14	0.39 (0.13 to 1.13
Donaldson 2006	21/57	18/42			<u> </u>	-				14.10	0.86 (0.53 to 1.40
Fiesseler 2006	19/44	20/41			_					14.09	0.89 (0.56 to 1.40
Friedman 2007	39/106	43/99			_	-				30.26	0.85 (0.61 to 1.19
Rowe 2007	14/64	20/62				ille in the second				13.83	0.68 (0.38 to 1.22
Total (95% CI)	385	353			<					100.00	0.74 (0.60 to 0.90
Test for heterogeneity	y: χ ² =6.21, df=6, P=0.4	0, I ² =3.4%			0.5						
Test for overall effect:	z=3.01, P=0.003		0.1	0.2	0.5	1	2	5	10		
us constitución a servición de la constitución de la constitución de la constitución de la constitución de la c			Favoi dexa	urs methaso	ne				vours acebo		

證據等級評定





Oxford Centre for Evidence-Based Medicine 2011 Levels of Evi

	(Level 1*)	(Level 2*)	Step 3 (Level 3*)	(Level 4*)	Step 5 (Level 5)
	· ·	Systematic review of surveys that allow matching to local circumstances**	Local non-random sample**	Case-series**	n/a
	of cross sectional studies with consistently applied reference		Non-consecutive studies, or studies without consistently applied reference standards**	Case-control studies, or "poor or non-independent reference standard**	Mechanism-based reasoning
• •	Systematic review of inception cohort studies	Inception cohort studies	Cohort study or control arm of randomized trial*	Case-series or case- control studies, or poor quality prognostic cohort study**	n/a
intervention help? (Treatment Benefits)	of randomized trials or <i>n</i> -of-1 trials	or observational study with dramatic effect	Non-randomized controlled cohort/follow-up study**	Case-series, case-control studies, or historically controlled studies**	Mechanism-based reasoning
COMMON harms? (Treatment Harms)	trials, systematic review	or (exceptionally) observational study with dramatic effect	Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**	Case-series, case-control, or historically controlled studies**	Mechanism-based reasoning
	trials or <mark>n-of-1 trial</mark>	Randomized trial or <mark>(exceptionally) observational</mark> study with dramatic effect			
` <i>'</i>	Systematic review of randomized trials	Kandomized trial	Non -randomized controlled conort/follow-up study**	Case-series, case-control, or historically controlled studies**	Piechanism-based reasoning

證據等級評定

× 等級 Graded down的原因:

- 1. 試驗品質 (quality)
- 2. 結果不精確 (imprecision)
- 3. 間接結果 (indirectness; study PICO與問題PICO不符合)符合)
 - 4. 文獻間的結果不一致(inconsistency between studies)
 - 5. 試驗結果之效果值(effect size)非常小
- × 等級 Graded up的原因:

試驗結果之效果值(effect size)大或非常大。

施行實證醫學的五大步驟

- *Ask:將臨床情境形成一個可回答的臨床問題
- * Acquire: 尋找最佳的文獻證據
- * Appraise: 嚴格評讀文獻
- * Apply: 應用於病人身上 3E
- × Audit: 對過程進行稽核

將證據應用在病患身上

- × 決定要將研究結果應用到病患身上前,應該要先問:
 - 1. 我的病患和研究中的病患是不是相差很大, 導致 試驗結果無法應用在他們身上?
 - 2. 我們是否也有此項治療?
 - 3. 對我的病患而言,治療的潛在效益會超過治療的潛在傷害嗎?
 - 4. 成本效益分析。

施行實證醫學的五大步驟

* Ask:將臨床情境形成一個可回答的臨床問題



* Acquire: 尋找最佳的文獻證據



☀ Appraise: 嚴格評讀文獻 VIIP

* Apply: 應用於病人身上 3E

× Audit: 對過程進行稽核

Audit

- × Ask: 我有提出任何結構完整的臨床問題嗎? ✓
- * Acquire: 我知道如何搜尋現有臨床領域中最佳的 證據來源,且在搜尋方面變得更有效率? ✓
- * Appraise: 對我而言,應用此研究證據之評讀指引 變得更簡單,而我亦盡全力做評讀了? 🗸
- × Apply: 我是否將搜尋到之最佳證據的結果盡力審 慎評估並應用到臨床工作中? 🗸



Thank you for your attention!